S1P/S1PR 

 57 Products   57 Products   190 Diseases   11246 News 


«12...949596979899100101102103104...109110»
  • ||||||||||  Gilenya (fingolimod) / Novartis, Mitsubishi Tanabe
    Journal:  Functional Connectivity Changes After Initial Treatment With Fingolimod in Multiple Sclerosis. (Pubmed Central) -  Apr 11, 2019   
    Cognitive improvement at month 6 was significantly (p < 0.05) related to baseline FC reduction in posterior cortical areas. This study shows significant changes in functional connectivity, both at baseline and after the execution of a simple motor task following 6 months of fingolimod therapy.
  • ||||||||||  Clinical, Review, Journal:  A review of the evidence for a natalizumab exit strategy for patients with multiple sclerosis. (Pubmed Central) -  Apr 9, 2019   
    ...In this case, dimethyl fumarate may carry a lower risk of relapse than interferon beta or glatiramer acetate...The evidence suggests that the washout period between natalizumab and fingolimod should not exceed 12 weeks. Finally, the limited evidence available for rituximab and alemtuzumab is promising, and further data on these and other newer therapies for RRMS are awaited.
  • ||||||||||  Gilenya (fingolimod) / Novartis, Mitsubishi Tanabe
    Clinical, Journal:  Clinical activity after fingolimod cessation: disease reactivation or rebound? (Pubmed Central) -  Apr 5, 2019   
    The present study showed that more than 26% of patients are at risk of having a relapse within 6 months after fingolimod discontinuation. Nevertheless, the risk of severe reactivations and rebound that we found is lower than that which has been previously described.
  • ||||||||||  fingolimod / Generic mfg., Ilaris (canakinumab) / Novartis
    Satellite Session: Stanley Research Group Workshop (Orlando Ballroom N) -  Apr 3, 2019 - Abstract #SIRS2019SIRS_340;    
    Each speaker will briefly present his/her data, leaving ample time for discussion. Oliver Howes, Institute of Psychiatry, Psychology & Neuroscience, Kings College Targeting microglia to treat schizophrenia: a monoclonal antibody approach Bill Deakin, University of Manchester Efficacy of methotrexate in schizophrenia and implications for pathogenesis Tom Weickert, University of New South Wales Reduction in peripheral C-reactive protein levels with canakinumab administration is related to reduced positive symptom severity in patients with schizophrenia and inflammation Faith Dickerson, Shephard Pratt Trials of Probiotics in Serious Mental Illness Alan Breier, Indiana University Novel Anti-inflammatory Treatments for Schizophrenia - Effects of Fingolimod and N-acetyl Cysteine on Brain Markers and Symptoms Golam Khandaker, University of Cambridge Inflammation as a Causal Risk Factor for Psychosis: evidence from population-based studies
  • ||||||||||  Journal:  Progressive Multifocal Leukoencephalopathy in the Absence of Typical Radiological Changes: Can We Make a Diagnosis? (Pubmed Central) -  Mar 28, 2019   
    Later, she was shifted to fingolimod as testing for John Cunningham polyoma virus (JCV) antibodies was positive...Intravenous steroids and intravenous immunoglobulin were given, and within a few weeks, the patient was stabilized and started to gradually improve. CONCLUSIONS In patients at risk for developing PML who present with typical clinical features, testing for JCV DNA is recommended even in the absence of typical radiological findings in order to prevent any delay in the diagnosis.
  • ||||||||||  Tysabri (natalizumab) / Biogen, FTY720, Gilenya (fingolimod) / Novartis, Mitsubishi Tanabe
    Clinical, Journal:  Real-Life Outcome in Multiple Sclerosis in the Czech Republic. (Pubmed Central) -  Mar 28, 2019   
    Treatment with natalizumab or fingolimod was associated with a lower risk of progression to EDSS 4. Our results link relapses to progression and indicate that the newer treatments have a better effectiveness, despite difficulties caused by small a sample size, administrative rules guiding treatment, and absence of a random comparator group.
  • ||||||||||  FTY720, Gilenya (fingolimod) / Novartis, Mitsubishi Tanabe
    Clinical, Journal:  Evaluation of Neutrophil Activation Status According to the Phenotypes of Adult Asthma. (Pubmed Central) -  Mar 28, 2019   
    Our results link relapses to progression and indicate that the newer treatments have a better effectiveness, despite difficulties caused by small a sample size, administrative rules guiding treatment, and absence of a random comparator group. Our findings suggest a useful in vitro PBN stimulation model for evaluating the neutrophil functional status and the therapeutic potentials of neutrophil-targeting candidates in asthmatics.
  • ||||||||||  FTY720, Gilenya (fingolimod) / Novartis, Mitsubishi Tanabe
    Journal:  Nodes of Ranvier in glaucoma. (Pubmed Central) -  Mar 23, 2019   
    After one week of systemic treatment with fingolimod, an immunosuppressant therapy for relapsing-remitting MS, DBA/2J mice showed a substantial reduction in node pathology and mild effects on axon morphology. These data suggest that neurophysiological deficits in the DBA/2J may be due to defects in intact axons and targeting node pathology may be a promising intervention for some types of glaucoma.
  • ||||||||||  Mayzent (siponimod) / Novartis
    Trial completion date, Trial initiation date, Trial primary completion date:  Efficacy, Safety and Tolerability of BAF312 Compared to Placebo in Patients With Intracerebral Hemorrhage (ICH). (clinicaltrials.gov) -  Mar 11, 2019   
    P2,  N=100, Recruiting, 
    These data suggest that neurophysiological deficits in the DBA/2J may be due to defects in intact axons and targeting node pathology may be a promising intervention for some types of glaucoma. Trial completion date: Mar 2020 --> Nov 2020 | Initiation date: Dec 2017 --> Jul 2018 | Trial primary completion date: Mar 2020 --> Nov 2020
  • ||||||||||  Mavenclad (cladribine) / EMD Serono
    Enrollment open, Trial initiation date, Trial primary completion date:  DELIVER-MS: Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS (clinicaltrials.gov) -  Jan 31, 2019   
    P4,  N=800, Recruiting, 
    Recruiting --> Completed | Trial completion date: May 2019 --> Jan 2019 Not yet recruiting --> Recruiting | Initiation date: Oct 2018 --> Jan 2019 | Trial primary completion date: Sep 2022 --> Dec 2022